Thus, the identification of colorectal cancer patients who could draw the highest benefit from anti-BRAF V600E targeted therapy should ideally be based not only on the presence of the BRAF V600E mutation but also take account of EGFR tumoral expression [39] for a personalized supplementation of BRAF targeting with cetuximab. Here, BRAF is linked to colorectal cancer.